Active substance
Acamprosate
- US FDA 7
- Health Canada 1
- NHS prices 1
- WHO EML 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ACAMPROSATE CALCIUM | 333MG | tablet, delayed release · oral | GLENMARK PHARMS LTD | Prescription | 16 Jul 2013 |
| ACAMPROSATE CALCIUM | 333MG | tablet, delayed release · oral | MYLAN | Prescription | 11 Mar 2014 |
| ACAMPROSATE CALCIUM | 333MG | tablet, delayed release · oral | ZYDUS PHARMS | Prescription | 26 May 2017 |
| ACAMPROSATE CALCIUM | 333MG | tablet, delayed release · oral | BIONPHARMA | Prescription | 18 Sep 2025 |
| ACAMPROSATE CALCIUM | 333MG | tablet, delayed release · oral | SOMERSET THERAPS LLC | Prescription | 16 Mar 2026 |
| CAMPRAL | 333MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet, delayed release · oral | FOREST LABS | Discontinued | 29 Jul 2004 |
| ACAMPROSATE CALCIUM | 333MG | tablet, delayed release · oral | BARR LABS DIV TEVA | Discontinued | 18 Nov 2013 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CAMPRAL | 02293269 | 333 MG | TABLET (DELAYED-RELEASE) · ORAL | MYLAN PHARMACEUTICALS ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Acamprosate 333mg gastro-resistant tablets | £22.04 | 168 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 24.5.1. Medicines for alcohol use disorders · core
Disorders due to use of alcohol
Oral > Solid > tablet: 333 mg
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.